Dementia Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2032

Dementia Drugs Market by Drug Class (Acetylcholinesterase Inhibitors, Amyloid Beta-directed Monoclonal Antibody, Antipsychotics, and Others), Indication (Alzheimer's disease, Parkinson's Disease Dementia, and Lewy Body Dementia), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of dementia, increasing advances in R&D and approval of new dementia drugs, rising awareness programs and early diagnosis across the globe.

The dementia drugs market was valued at USD 9,825.24 million in 2024, growing at a CAGR of 6.06% during the forecast period from 2025 to 2032 to reach USD 15,597.17 million by 2032. The global dementia drugs market is growing due to the increasing prevalence of dementia worldwide. Additionally, advances in R&D, coupled with the approval of new drugs, are expanding therapeutic options, enabling more targeted and efficacious treatments that address diverse dementia types and stages. Furthermore, the rising awareness programs and initiatives promoting early diagnosis are encouraging timely intervention, which boosts the market further by increasing the patient base seeking treatment. Together, these factors are creating a favorable environment for the dementia drug market, during the forecast period from 2025 to 2032.

Dementia Drugs Market Dynamics:

According to the World Health Organization (WHO) in 2023, over 55 million people were living with dementia globally, with nearly 10 million new cases diagnosed each year. More than 60% of people with dementia live in low- and middle-income countries, where healthcare infrastructure is often limited. By 2050, Alzheimer's Disease International projects that the global dementia population will reach 139 million, with the most significant increases occurring in low- and middle-income regions. Additionally, a new case of dementia is diagnosed every 3 seconds, indicating an accelerating need for effective treatment options.

As the number of people living with dementia continues to rise, the demand for drugs to manage cognitive decline among patients intensifies. Dementia medications, which focus on reducing cognitive impairment and managing psychological and behavioral symptoms, play a critical role in maintaining the quality of life for patients. The growth in the demand for these medications is expected to drive significant expansion in the dementia drugs market from 2024 to 2030.

Aging is the most significant risk factor for dementia, with the probability of developing dementia doubling approximately every five years after age 65. For instance, the Alzheimer's Society of the UK reports that around 2 in 100 people aged 65 to 69 have dementia, a figure that climbs to 33 in 100 for individuals over the age of 90. Neurodegenerative diseases, such as Alzheimer's and vascular dementia, gradually develop over the years, so the longer a person lives, the higher their risk of cognitive decline and dementia.

In addition to age, genetic factors are critical in influencing dementia risk. Genes associated with dementia are categorized as either familial or risk genes. Familial genes guarantee dementia development if inherited, typically leading to early-onset symptoms in a person's 50s or 60s. Although rare, these genes account for about one-third of frontotemporal dementia cases. Risk genes, however, only increase the likelihood of developing dementia without assuring it. Over 20 risk genes have been identified to date, with most contributing to an elevation in dementia risk. The growing understanding of genetic risk factors is expected to drive the development of personalized treatments and the dementia drug market in the coming years.

Additionally, the recent advances in dementia research and the approval of new dementia drugs are fundamentally reshaping the treatment landscape, marking a shift towards addressing underlying disease mechanisms and significantly boosting the global dementia drug market. Over the past few years, the emergence of innovative therapies like lecanemab and donanemab has been groundbreaking, particularly for Alzheimer's disease, spurring global demand for these treatments. For instance, in January 2023, the FDA granted accelerated approval to Leqembi (lecanemab), a drug targeting amyloid beta plaques, one of the key pathological hallmarks of Alzheimer's. This medication has shown effectiveness in slowing cognitive decline in patients with early-stage Alzheimer's, offering renewed hope for the long-term management of dementia. Thus, the factors mentioned above are expected to boost the overall market of dementia drugs across the globe during the forecast period from 2025 to 2032.

However, high clinical trial failure rates and severe side effects of dementia drugs may hinder the future market of dementia drugs across the globe during the forecasted period.

Dementia Drugs Market Segment Analysis:

Dementia Drugs Market by Drug Class (Acetylcholinesterase Inhibitors, Amyloid Beta-directed Monoclonal Antibody, Antipsychotics, and Others), Indication (Alzheimer's disease, Parkinson's Disease Dementia, and Lewy Body Dementia), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The acetylcholinesterase inhibitors category in the dementia drugs market is estimated to dominate the market with a market share of 75.24% in 2024. This can be attributed to its treatment adherence for multiple forms of dementia, its specificity, and various other advantages that these inhibitors provide, during the forecast period. AChEIs work by inhibiting the action of acetylcholinesterase, resulting in higher acetylcholine concentrations in the synaptic cleft. This method is especially advantageous in dementia, as cholinergic neuron degeneration causes lower acetylcholine levels, which contributes to cognitive loss.

AChEIs have been proven to improve cognitive performance to a minor degree. According to studies, people on AChEIs may exhibit less cognitive decline than those who do not receive these medicines. Further, research has shown that AChEI therapy is associated with decreased all-cause mortality rates in dementia patients. For example, galantamine is known for its potential to lower the chance of acquiring severe dementia. It was related to a considerable reduction in progression to severe dementia stages when compared to non-users. In July 2024, the U.S. FDA approved ALPHA-1062 (Zunveyl(R)), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer's disease. With further research on AChEIs advancing, the importance of ALPHA-1062 and similar molecules as therapeutic options for dementia becomes increasingly evident.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of dementia drugs across the globe.

North America is expected to dominate the overall dementia drugs market:

Among all regions, North America is estimated to hold the largest share of 44.45% in the global dementia drugs market in 2024, growing at a CAGR of 6.23% during the forecast period from 2025 to 2032. This can be attributed to the rising prevalence of dementia in the region. Moreover, the rise in the number of drug approvals granted to the key manufacturers as a treatment for dementia in the region, increasing government initiatives and funding to various drug developmental projects associated with dementia, are expected to drive the regional dementia drugs market in the forthcoming years.

According to the data provided by the Alzheimer's Association 2024, it was estimated that nearly 7 million people in the United States are living with Alzheimer's, and by 2050 this number is projected to rise to nearly 13 million by 2050.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2024), in 2021, there were more than 586 traumatic brain injury-related hospitalizations per day in the United States. The increasing prevalence of Alzheimer's disease and cases of traumatic brain injury (TBI), both known to heighten the risk of dementia, contribute to greater demand for dementia drugs. As more individuals are diagnosed due to these factors, the need for medications that manage symptoms and slow cognitive decline rises, boosting the dementia drug market.

Further, various product approvals and product launches in the domain of dementia drugs will also help to boost the growth of the dementia drugs market in the region. For instance, in January 2023, the U.S. Food and Drug Administration approved Leqembi via the accelerated approval pathway for the treatment of Alzheimer's disease.

Thus, the above-mentioned factors are expected to escalate the market of dementia drugs in the region.

Dementia Drugs Market Key Players:

Some of the key market players operating in the dementia drugs market include Eli Lilly and Company, Aurobindo Pharma, Essential Pharma, Biogen, Novartis AG, Zydus Group, Corium, LLC, Apotex Inc., Luye Pharma Group, H. Lundbeck A/S, Sun Pharmaceutical Industries Ltd., Green Valley Inc., Sumitomo Pharma Co., Ltd., and others.

Recent Developmental Activities in the Dementia Drugs Market:

• In July 2024, Eli Lilly's Kisunla (donanemab) was approved for adults in the early stages of Alzheimer's, encompassing those with mild cognitive impairment (MCI) and mild dementia with confirmed amyloid pathology. By targeting amyloid plaques, Kisunla presents a shift towards treatments that address disease progression rather than simply managing symptoms, thus broadening therapeutic options.
• In July 2024, Alpha Cognition's ZUNVEYL(R) (benzgalantamine), formerly known as ALPHA-1062, was approved by the FDA for treating mild to moderate Alzheimer 's-related dementia. This drug is designed to manage cognitive symptoms effectively in adults, providing a new treatment avenue for patients in early disease stages, and contributing to the growing demand for dementia therapeutics.
• In May 2023, the FDA approved Rexulti (brexpiprazole) specifically to manage agitation symptoms associated with Alzheimer 's-related dementia. This approval expanded the treatment options available for managing behavioral symptoms, which forms a critical unmet need for both patients and caregivers.

Key Takeaways From the Dementia Drugs Market Report Study

• Market size analysis for current dementia drugs size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the dementia drugs market.
• Various opportunities available for the other competitors in the dementia drugs market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current dementia drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for dementia drugs market growth in the coming future?

Target Audience Who Can be Benefited From This Dementia Drugs Market Report Study

• Dementia drug product providers
• Research organizations and consulting companies
• Dementia drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in dementia drugs
• Various end-users who want to know more about the dementia drugs market and the latest technological developments in the dementia drugs market.

Frequently Asked Questions for the Dementia Drugs Market:

1. What are dementia drugs?

• Peptide-drug conjugates (PDCs) are an innovative class of targeted therapeutics designed for precise drug delivery, particularly in cancer treatment. They consist of three key components: a peptide, a linker, and a cytotoxic or radioactive drug. The peptide, a short amino acid sequence, selectively binds to specific receptors on target cells, enabling enhanced tissue penetration and targeted delivery.

2. What is the market for dementia drugs?

• The dementia drugs market was valued at USD 9,825.24 million in 2024, growing at a CAGR of 6.06% during the forecast period from 2025 to 2032 to reach USD 15,597.17 million by 2032.

3. What are the drivers for the global dementia drugs market?

• The global dementia drugs market is growing due to the increasing prevalence of dementia worldwide. Additionally, advances in R&D, coupled with the approval of new drugs, are expanding therapeutic options, enabling more targeted and efficacious treatments that address diverse dementia types and stages. Furthermore, the rising awareness programs and initiatives promoting early diagnosis are encouraging timely intervention, which boosts the market further by increasing the patient base seeking treatment. Together, these factors are creating a favorable environment for the dementia drug market, during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global dementia drugs market?

• Some of the key market players operating in dementia drugs are Eli Lilly and Company, Aurobindo Pharma, Essential Pharma, Biogen, Novartis AG, Zydus Group, Corium, LLC, Apotex Inc., Luye Pharma Group, H. Lundbeck A/S, Sun Pharmaceutical Industries Ltd., Green Valley Inc., Sumitomo Pharma Co., Ltd., and others.

5. Which region has the highest share in the global dementia drugs market?

• North America region is anticipated to dominate the overall dementia drugs market due to the rising prevalence of dementia in the region. Moreover, the rise in the number of drug approvals granted to the key manufacturers as a treatment for dementia in the region, increasing government initiatives and funding to various drug developmental projects associated with dementia, are expected to drive the regional dementia drugs market in the forthcoming years.